FeesSafety
Pluang+

Glycomics market to nearly double to $4.76B by 2032 driven by AI and biologics demand

Market News
29 Oct 2026, 17:07 WIB
Globe News Wire
View Source
Bullish
Glycomics market to nearly double to $4.76B by 2032 driven by AI and biologics demand

The global glycomics/glycobiology market is projected to grow from $2.32 billion in 2026 to $4.76 billion by 2032, at a CAGR of 12.66%. Growth is driven by advances in AI, precision medicine, and increasing regulatory demands for biologics quality. Key applications include diagnostics, therapeutics, and biopharmaceutical production, with North America, Europe, and Asia-Pacific leading development. The report highlights the importance of early glycosylation profiling, standardized methods, and cross-sector collaboration for market success.

The glycomics/glycobiology market is forecast to reach USD 4.76 billion by 2032, driven by AI, precision medicine, and biologics demand. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 29, 2026 20:51 WIB: 126 of 150 stocks rose, 24 fell. Notable movers include ALNY at USD 194.78 (-16.19%), NUWE at USD 6.50 (+15.04%), and MESO at USD 15.34 (+14.56%).

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App